Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/10/2017 01/11/2017 01/12/2017 01/13/2017 01/17/2017 Date
59.98(c) 56.8(c) 56.55(c) 56.22(c) 56.28(c) Last
6 103 701 20 497 892 9 977 917 7 660 198 10 416 327 Volume
+0.42% -5.30% -0.44% -0.58% +0.11% Change
More quotes
Financials ($)
Sales 2016 19 320 M
EBIT 2016 5 355 M
Net income 2016 4 639 M
Debt 2016 175 M
Yield 2016 2,78%
Sales 2017 19 969 M
EBIT 2017 5 681 M
Net income 2017 4 656 M
Finance 2017 798 M
Yield 2017 2,90%
P/E ratio 2016 20,40
P/E ratio 2017 20,00
EV / Sales2016 4,88x
EV / Sales2017 4,67x
Capitalization 94 057 M
More Financials
Company
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products.Its pharmaceutical products include chemically-synthesized drugs or small molecules and an increasing portion of products produced from... 
Sector
Pharmaceuticals
Calendar
01/26 | 01:00pmEarnings Release
More about the company
Surperformance© ratings of Bristol-Myers Squibb Co
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB CO
01/14 BRISTOL MYERS SQUIBB : Founders Financial Securities adds Bristol-Myers Squibb C..
01/12 BRISTOL MYERS SQUIBB : Janssen Enters Immunotherapy Clinical Collaboration with ..
01/12 BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Have Provided New Infor..
01/12 BRISTOL MYERS SQUIBB : to Present at J.P. Morgan Healthcare Conference
01/12 BRISTOL MYERS SQUIBB : Researchers from Bristol-Myers Squibb Discuss Findings in..
01/12 BRISTOL MYERS SQUIBB : Details Findings in Medicinal Chemistry (Difluorocyclobut..
01/12 BRISTOL MYERS SQUIBB : Data on Biosensing Reported by Researchers at Bristol-Mye..
01/12 BRISTOL MYERS SQUIBB : Announces Immunotherapy Clinical Collaboration with Janss..
01/12 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Provides New Data on H..
01/12 BRISTOL MYERS SQUIBB : Investigators from Bristol-Myers Squibb Release New Data ..
More news
Sector news : Pharmaceuticals - NEC
01:56aDJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- 2nd Update
12:05aDJAllergan Admits to Disclosure Violations During Valeant Bid
01/17 Allergan to pay $15 million over failing to disclose merger talks
01/17DJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- Update
01/17DJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on BRISTOL-MYERS SQUIBB CO 
2016Attractive price levels
More Strategies
Latest Tweets
01/17$BMY testing green… look below 100MA & fail. If she closes strong, can be.. 
01/17Generics set to undercut blockbusters from Merck, Novartis and Bristol-Myers ..
6
01/17$BMY handling herself fairly well intra-day off the lows. Eyeing this one clo.. 
01/17Want the latest analyst ratings on $ADES $NVGN $PWR $BMY $SZMK? Get Them Deli.. 
01/17Why Bristol-Myers Squibb Could be a Takeover Target Soon  
More tweets
Qtime:97
News from SeekingAlpha
01/13 BIOTECHS : What The 'Trump Dump' And CVS's EpiPen Move May Mean
01/12 Merck gets upgrades on leadership in drug/chemo combo race
01/11 Allergan CEO also has a Twitter account
01/11 JPMorgan Day Two Roundup - All Talk, Very Little Action
01/11 Merck Muscles Into Bristol's Combo Space
Advertisement
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 62,5 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-3.70%94 057
JOHNSON & JOHNSON-0.30%312 507
ROCHE HOLDING LTD.1.29%200 476
PFIZER INC.-1.29%194 551
NOVARTIS AG-2.70%185 185
MERCK & CO., INC.4.43%169 509
More Results